It stimulates the proliferation of muscle satellite cells, which are important for muscle regeneration and repair
Waist circumference, systolic blood pressure (BP), triglycerides, and non-high-density lipoprotein cholesterol (non-HDL-C) improved significantly, indicating broad cardiometabolic improvements
Introduction The presence of type 2 diabetes or maternal obesity during pregnancy increases the risk of adverse pregnancy outcomes and birth defects ( In a non-pregnant patient with type 2 diabetes, a GLP-1 agonist or SGLT2 inhibitor can be prescribed if adequate glycemic control is not achieved with metformin, sulphonylureas or (basal) insulin, or if weight reduction, hypoglycemia prevention or reduction of cardiovascular risk is the treatment goal ( Despite the fact that these novel glucose lowering medications have seen wide uptake in clinical practice, information regarding the safety of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation is exceedingly scarce
Beyond gastrointestinal symptoms, other adverse effects observed in trials include injection site reactions (such as redness, bruising, or mild swelling), fatigue, dizziness, and small mean increases in heart rate
The medication is also approved for the treatment of moderate to severe obstructive sleep apnea (OSA)